Foxchart.com
Natera, Inc. (NTRA)
272.66  -0.23 (-0.08%)  07-14 16:00
Open: 276.73
High: 278.505
Low: 271.23
Volume: 954,766
Market Cap: 39,049(M)
PE Ratio: -171.48
Exchange: NASDAQ Global Select
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell buy
Resistance 2: 336.43
Resistance 1: 288.04
Pivot price: 270.24
Support 1: 239.07
Support 2: 208.79
52w High: 288.04
52w Low: 131.811
Zoom in Zoom out
Draw lines
Horizontal lines
Parallel lines
Fibonacci lines
Remove studies
Shot and share

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

Financials
EPS -267580000.000
Book Value 0.000
PEG Ratio 265.83
Gross Profit 25.867
Profit Margin (%) 0.00
Operating Margin (%) -9.05
Return on Assets (ttm) -12.4
Return on Equity (ttm) -9.1
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
×
Share on Facebook Tweet this page

Foxchart:  |  United States  |  Canada  |  United Kingdom  |  Australia  |  New Zealand  |  Singapore  |  India

©Foxchart.com All Rights Reserved. Foxchart.com | United States NYSE NASDAQ AMEX stock markets, stock quotes and stock technical analysis charts. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither Foxchart.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX